94 results
424B3
RGBP
Regen BioPharma Inc
29 Apr 24
Prospectus supplement
4:08pm
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS
8-K
EX-10.1
RGBP
Regen BioPharma Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:07pm
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS WHEREOF, the parties have
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application … States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application of HemaXellerate qualifies for Orphan
8-K
EX-10.1
oj8kw
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
yzvjjrw
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
lx6fg s5cjdnkcaqbnaw
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
ibpq25ak
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
ku7f3kqy
15 May 23
Prospectus supplement
10:25am